Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body's interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/17/22	$105,000,000	Series B	Ajax Health Boxer Capital BVF Partners Commodore Capital Deep Track Capital General Atlantic RA Capital Management RTW Investments	undisclosed